HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Launches Safe Use Initiative; Details TBA Following Stakeholder Input

This article was originally published in The Tan Sheet

Executive Summary

FDA expects to accomplish the goals of its Safe Use Initiative through a combination of voluntary moves by industry and regulatory activities

You may also be interested in...



FDA Warns Oversized, Unmarked Droppers Could Lead To Vitamin D Overdose

FDA recommends firms limit the size of droppers accompanying liquid vitamin D supplements for infants to the maximum recommended daily amount to reduce the risk of overdose

Drug Industry Avoids FDA's "Blunt Tools" With Safe Use Initiative Progress

Efforts by firms and other pharmaceutical industry stakeholders to drive FDA's Safe Use Initiative agenda lower the likelihood of the agency intervening with enforcement action, according to Principal Deputy Commissioner Josh Sharfstein

Firms Must Pair Education With Mechanical Constraints To Reduce Overdoses

Manufacturers must "engineer" safety constraints into acetaminophen products to reduce the risk of overdose and liver damage because consumer education alone is not enough, a joint FDA advisory committee said June 30

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS135596

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel